Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure

Abstract

Objectives: The purpose of this study was to assess the relationship between biomarkers of renin-angiotensin-aldosterone system (RAAS) activation and decongestion strategies, worsening renal function, and clinical outcomes.

Background: High-dose diuretic therapy in patients with acute heart failure (AHF) is thought to activate the RAAS; and alternative decongestion strategies, such as ultrafiltration (UF), have been proposed to mitigate this RAAS activation.

Methods: This study analyzed 427 AHF patients enrolled in the DOSE-AHF (Diuretic Optimization Strategies in Acute Heart Failure) and CARRESS-HF (Cardiorenal Rescue Study in Acute Decompensated Heart Failure) trials. We assessed the relationship between 2 markers of RAAS activation (plasma renin activity [PRA] and aldosterone) from baseline to 72 h and 96 h and decongestion strategy: high- versus low-dose and continuous infusion versus bolus furosemide for DOSE-AHF and UF versus stepped pharmacologic care for CARRESS-HF. We determined the relationships between RAAS biomarkers and 60-day outcomes.

Results: Patients with greater RAAS activation at baseline had lower blood pressures, lower serum sodium levels, and higher blood urea nitrogen (BUN) concentration. Continuous infusion furosemide and UF were associated with greater PRA increases (median: +1.66 vs. +0.66 ng/ml/h with continuous vs. bolus infusion, respectively, p = 0.021; +4.05 vs. +0.56 ng/ml/h with UF vs. stepped care, respectively, p = 0.014). There were no significant differences in RAAS biomarker changes with high- versus low-dose diuretic therapy (both: p > 0.5). Neither baseline log PRA nor log aldosterone was associated with increased death or HF hospitalization (hazard ratio [HR] for a doubling of 1.05; 95% confidence interval [CI]: 0.98 to 1.13; p = 0.18; and HR: 1.13; 95% CI: 0.99 to 1.28; p = 0.069, respectively). The change in RAAS biomarkers from baseline to 72 and 96 h was not associated with outcomes (both: p > 0.5).

Conclusions: High-dose loop diuretic therapy did not result in RAAS activation greater than that with low-dose diuretic therapy. UF resulted in greater PRA increase than stepped pharmacologic care. Neither PRA nor aldosterone was significantly associated with short-term outcomes in this cohort. (Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure [DOSE-AHF]; NCT00577135; Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome [CARRESS]; NCT00608491).

Keywords: RAAS activation; acute heart failure; cardiorenal syndrome; decongestion; diuretics; outcomes; ultrafiltration.

Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1. Study patient population

Abbreviation: Stepped Pharm indicates stepped pharmacologic therapy.

Figure 2. Plasma renin activity (PRA) change from baseline based on decongestion strategy

Values are presented as median (closed circle) and interquartile range (whiskers). P-values come from linear regression models for 72 or 96 hour PRA adjusted for baseline PRA, baseline ACE-I/ARB use, and baseline aldosterone antagonist use where a log transformation is applied to both the baseline and follow-up PRA measure Abbreviations: Bolus indicates bolus furosemide; Contin, continuous infusion furosemide; Low, low-dose furosemide; High, high-dose furosemide; Pharm, stepped pharmacologic therapy; UF, ultrafiltration.

Figure 3. Aldosterone change from baseline based on decongestion strategy

Values are presented as median (closed circle) and interquartile range (whiskers). P-values come from linear regression models for 72 or 96 hour aldosterone adjusted for baseline aldosterone, baseline ACE-I/ARB use, and baseline aldosterone antagonist use where a log transformation is applied to both the baseline and follow-up aldosterone measure Abbreviations: Bolus indicates bolus furosemide; Contin, continuous infusion furosemide; Low, low-dose furosemide; High, high-dose furosemide; Pharm, stepped pharmacologic therapy; UF, ultrafiltration.

Figure 4. Scatterplots of net fluid loss and the change in biomarkers of RAAS activation from baseline to 72 hours (DOSE-AHF) or 96 hours (CARRESS-HF)

Abbreviation: PRA indicates plasma renin activity.